- Home
- OMH vs VRAX Comparison
OMH vs VRAX Comparison
Compare OMH & VRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OMH | VRAX |
|---|---|---|
| Founded | 2015 | 2013 |
| Country | Singapore | United Kingdom |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.6M | 2.9M |
| IPO Year | 2023 | 2022 |
Fundamental Metrics
Financial Performance| Metric | OMH | VRAX |
|---|---|---|
| Price | $0.85 | $0.40 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 184.5K | ★ 15.4M |
| Earning Date | 04-17-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $10,264,748.00 | $2,986.00 |
| Revenue This Year | $28.40 | $217,274.83 |
| Revenue Next Year | $23.07 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 78.86 | N/A |
| 52 Week Low | $0.59 | $0.35 |
| 52 Week High | $5.10 | $3.20 |
Technical Indicators
Market Signals| Indicator | OMH | VRAX |
|---|---|---|
| Relative Strength Index (RSI) | 38.43 | 42.56 |
| Support Level | $0.79 | $0.39 |
| Resistance Level | $1.15 | $0.43 |
| Average True Range (ATR) | 0.07 | 0.07 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 4.62 | 4.67 |
Price Performance
Historical ComparisonAbout OMH Ohmyhome Limited
Ohmyhome Ltd is a data and technology-driven property technology company based in Singapore. Through its subsidiaries, it operates a one-stop-shop property platform that provides end-to-end property solutions and services for its customers, which comprises brokerage services and emerging and other services, such as home renovation and furnishing services, listing and research, mortgage referral, legal services, and insurance referral services. The company derives its revenues from two sources: revenue from brokerage services, property management services, and revenue from emerging and other services.
About VRAX Virax Biolabs Group Limited
Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes (HSV-1) and Human Papillomavirus (HPV).